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Abstract 
Programmable nucleases, including Zinc Finger Nucleases (ZFNs), Transcription 
Activator-Like Effector Nucleases (TALENs), and Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR) have enhanced our ability to edit the genome by 
sequence specific generation of a double strand break (DSB) with subsequent homology 
directed repair (HDR) of the DSB. However, the efficiency of the HDR pathway is limited 
in non-dividing cells, which encompass the majority of in the body. Therefore, the HDR-
mediated genome editing approach has, reportedly, limited in vivo applicability. Here 
we discuss a mutation-type oriented viewpoint of strategies devised over the last years 
to circumvent this problem, their possible applications and limitations.
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Glossary 
Base editors (BE): a fusion protein consisting of a cytidine deaminase and a dCas9/Cas9 
nickase, capable of performing a C to T base conversion. 
Clustered regularly interspaced short palindromic repeats (CRISPR): a defensive tool of 
archea and bacteria which has been harnessed as a programmable nuclease for genome 
editing in animals and plants. 
Dead Cas9 (dCas9): a catalytically inactive form of cas9 generated by two silencing 
mutations in RuvC and HNH catalytic domains of Cas9 (D10A and H840A).  
Homology directed repair (HDR): One of the two main DSB repair pathways which uses 
a template to restore the lost sequence at DSB site. Repair template can be a sister 
chromatid, other chromosome or duplicated sequence on the same or other 
chromosomes as well as exogenously provided templates. 
Homology-independent targeted integration (HITI): a gene editing knock in strategy 
with a special design based on NHEJ ligation of a donor DNA mainly in a correct 
orientation. 
Homology-mediated end joining (HMEJ): a gene editing strategy which uses a donor 
with homology arms similar to HDR donors but the donor is excised from the backbone 
inside the cell. 
Microhomology-mediated end joining (MMEJ): an end joining repair pathway works 
independent of Ku and relies on microhomologous sequences of 5-25 bp size for sticking 
the broken ends. 
Mismatch repair (MMR): a major evolutionary conserved DNA repair pathway which 
corrects base-base mismatches and insertion deletion loop of newly synthetized DNA. 
Non-homologous end-joining (NHEJ): One of the two main DSB repair pathways which 
is donor-independent and uses heterodimeric enzyme consist of proteins Ku70 and 
Ku80, the catalytic subunit of protein kinase and ligase IV/XRCC4. 
Obligate ligation-gated recombination (ObLiGaRe): a gene editing knock in strategy 
resembling HITI, which uses obligated heterodimeric ZFN or TALEN.  
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Precise integration into target chromosome (PITCH): a gene editing knock in strategy 
based on MMEJ pathway. 
Protospacer adjacent motif (PAM): a conserved motif which might reside in 5’ or 3’ 
location relative to protospacer and is used by CRISPR system to determine the invader 
from endogenous target sequences.  
Recombinase Cas9 (recCas9): a chimeric protein made of a serine recombinase and a 
cas9. 
Transcription coupled NER (TC-NER): a subtype of nucleotide excision repair pathway 
which removes lesions from template DNA in actively transcribed genes.  
Transcription activator-like effector nuclease (TALEN): a programmable nuclease made 
by fusion of TALE protein and FokI cleavage domain. TALEN consist of a series of 33 to 
35 amino acids repeats and a FokI cleavage domain. Dimerization of FokI monomers 
from two arms of TALEN results in DSB formation. 
Zinc finger nuclease (ZFN): a programmable nuclease made by fusion of zinc finger 
proteins and a FokI cleavage domain. DSB forms upon FokI dimerization of two zinc 
finger proteins. 
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A case for novel in vivo gene editing strategies  
There are around 5000 monogenic disorders in humans wherein the gene mutation 
causes impaired function of terminally differentiated tissue cells 
(www.omim.org/statistics/geneMap). Although rare individually, collectively, 
monogenic disorders constitute a common health problem (http://www.orpha.net). A 
number of therapies exist for some monogenic of these disorders, including among 
others, organ transplantation or cell therapy, gene augmentation, RNA or protein 
therapies or metabolic manipulation. However, many monogenic disorders remain 
untreatable [5-9]. As the basic cause of these diseases is a mutated gene, gene editing 
would theoretically be able to resolve all of these disorders. In vivo genome editing has 
the advantage that gene expression remains under the control of the endogenous gene 
regulatory elements; and that the therapy is permanent [1]. However, to reverse the 
genetic defects in terminally differentiated cells, therapies that can correct the genetic 
defect in non-dividing cells affected by the monogenic disease is required, which 
remains a major challenge. 
Genome editing using programmable nucleases such as ZFNs (see Glossary) , TALENs, 
and CRISPR/Cas is based on generating DNA double strand breaks (DSB) in the sequence 
to be edited (Box 1) [10]. Such a DSB is sensed by cellular repair pathways, both non-
homologous end-joining (NHEJ) or homology directed repair (HDR). While NHEJ is 
generally known to be an error prone pathway causing insertions and deletions (indels), 
which occurs independent of a donor template, HDR is donor-dependent and is 
considered to be an error-free pathway. Therefore, HDR has been extensively tested 
and used for precise gene editing. As HDR is restricted to the S and G2 phases of the cell 
cycle, this approach is not suited for editing and repairing the genome in non-dividing 
cells with the exception of some specific circumstances (Box 2) [11]. Recently a number 
of novel genome-editing strategies [e.g. obligate ligation-gated recombination 
(ObLiGaRe), homology-independent targeted integration (HITI), Cpf1, precise 
integration into target chromosome (PITCH), homology-mediated end joining (HMEJ), 
5 
 
base editing, and recombinase cas9 (recCas9)] have been developed that might make it 
possible to correct genetic mutations in non-dividing cells [12-17].  
Box 1. CRISPR-Cas9 
The CRISPR system is a defensive tool of archaea and bacteria against invading DNA that has been 
harnessed for genome editing in plants and animals [18]. This CRISPR system provides adaptive 
immunity in prokaryotes, by degrading foreign DNA and inserting these sequences in CRISPR loci 
where they are separated by repetitive sequences [19]. Subsequent invasion results in 
transcription of these sequences, named CRISPR RNA’s (crRNAs, or also guide RNA’s (gRNAs)), that 
then guide Cas effector protein to the complementary DNA sequence in the invading organism. 
Upon binding, the target region is cleaved by a single-protein Cas effector protein (class 2) or large 
multi- subunit protein complexes (class 1). These two classes of Cas effector proteins are further 
diversified into 6 types (type I-III (class 1) and type IV-VI (class 2). The invader sequence is 
discriminated from the native sequence by a short, conserved sequence, named the protospacer 
adjacent motif (PAM), located on the non- complementary strand. 
CRISPR-Cas9, and especially Cas9 from streptococcus pyogenes (SpCas9), is the most extensively 
studied class 2 system. Cas9, as well as few other Cas effectors, require a second RNA molecule 
called trans-activation crRNA (tracr-RNA) [20]. During transcription of the crRNA, a long transcript 
(pre-crRNA) is formed, and repetitive sequences bind to the complementary regions in the 
tracrRNA. Host cell-derived RNAse III then cleaves these RNA duplexes from the pre-crRNA. 
tracrRNA and crRNA can be used as single chimeric sequence, named single guide RNA (sgRNA). 
Subsequent to recognition of the PAM sequence at the 3’ of the target sequence, Cas9 unwinds the 
target sequence allowing target recognition by the gRNA. This unwinding forms an R- loop that 
progresses away from the PAM sequence [21]. Cas9 cleaves both DNA strands 3 nucleotides 
upstream of the PAM sequence, by two distinct domains, namely the HNH and RuvC/RNaseH-like 
endonuclease domains. Perfect complementation to the target sequence allows for a 
conformational change in the HNH domain, which then regulates the cleavage of the RuvC domain 
via allosteric communication, enabling high-fidelity cleavage of both strands [22, 23]. 
This review discusses these recent strategies for in vivo gene editing in non-dividing 
cells. We not only describe novel NHEJ-based strategies in a mutation type-oriented 
viewpoint (Figure 1), but also suggest approaches that would enable the use of these 
strategies for a wider range of mutations than those described in the initial reports (Box 
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3). We also discuss the recent evidence that HDR may not be impossible in non-dividing 
cells.  
We first describe in vivo gene editing strategies requiring a donor template, followed by 
strategies operative in a donor-independent way (Figure 1).  We also briefly discuss the 
application of such strategies in other setting such as quiescent stem cells, cancer 
modelling, organ cultures and etc. (Box 4). 
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Box 2. HDR-dependent In vivo gene editing in non-dividing cells  
The major challenge for the in vivo use of programmable nucleases in non-dividing compared with 
dividing cells is the low efficiency of HDR [1]. HDR is restricted to the S and G2 phases of the cell cycle, 
which makes non-dividing cells not amenable to precise gene editing and repair by HDR [1].  
Nevertheless, there are a number of circumstance wherein HDR mediated gene editing has been used 
successfully in non-dividing cells (Table I):  
(i) the corrected cells have a significantly increased fitness over non-corrected cells, i.e. even if only very 
few cells have been genetically corrected, they can re-enter the cell cycle, divide and repopulate the 
organ (for instance genetically corrected mature hepatocytes in hereditary tyrosinemia type I, copper 
storage disorder and biliary acid transporter defects [2, 3]);  
(ii) the gene functions in a non-cell autonomous manner, and even correction of a limited number of 
cells is sufficient to treat the disease (for instance for factor VIII in haemophilia [4]);  
(iii) the protein has a cell-autonomous function but can also be taken up from the extracellular milieu; 
and the levels of protein secreted from a limited number of edited cells is sufficient to reverse the 
phenotype (for instance in lysosomal storage disorders such as mucopolysaccharidosis (MPS) I and II  
[5]). 
Table I. Clinical trials and preclinical examples of HDR dependent in vivo gene editing in non- dividing cells 
 
Disease Type Specific 
circumstance 
Target Cell Nuclease  
 
Approach Study 
phase 
Clinicaltrials.Gov 
Identifier/Ref 
Hemophilia B Non-cell 
autonomous 
Hepatocyte  ZFN Knock in Phase I   NCT02695160 
MPS I Extracellular 
uptake 
Hepatocyte ZFN 
 
Knock in Phase I NCT02702115 
MPS II Extracellular 
uptake 
Hepatocyte ZFN 
 
Knock in Phase I NCT03041324 
Tyrosinemia Increased 
fitness 
Hepatocyte  Cas9 Correction Preclinical [3] 
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Donor dependent strategies for in vivo genome editing in non-dividing cells 
To bypass the problem of the low efficiency of HDR in non-dividing cells, it is possible to 
exploit other DNA repair pathways for precise in vivo gene editing. Several non-
homologous repair methods require -as for HDR - that a donor template is available, but 
they can also operate throughout the interphase cell cycle and can, therefore, 
theoretically be exploited for genome editing in non-dividing cells [11].  
Non-homologous end-joining (NHEJ)-based strategies (e.g. ObliGaRe, HITI, Cpf1) 
Although NHEJ is known to be a fallible repair system, describing NHEJ as a mostly 
‘error-prone’ pathway may be an oversimplification as there is significant evidence that 
NHEJ can operate accurately and, hence, contribute to precise gene repair in non-
dividing cells [24]. Here we describe three NHEJ based methods based on blunt (HITI) or 
sticky (ObLiGaRe and Cpf1) DSB ends generated by nucleases (Figure 2). 
Obligate ligation-gated recombination (ObLiGaRe) is a knock-in NHEJ based strategy 
devised by Maresca and colleagues [25]. ObLiGaRe is based on obligate heterodimeric 
ZFNs or TALENs to form a FokI heterodimer that then cleaves the target sequence. The 
ObLiGaRe system is based on ligation of a donor plasmid into a DSB site by designing a 
ZFN (or TALEN) target site in the donor plasmid identical to the one in the genome. The 
ZFN site in the donor is in the reverse orientation to preclude reconstruction of the ZFN 
target site (Figure 2 a and 2b). Using this system in dividing cells, a precise in vitro knock-
in of a 15kb insert sequence was achieved in 3 of 4 clones, but only after antibiotic-
based selection. As ObLiGaRe is based on NHEJ, it could be employed in non-dividing 
cells, although this still needs to be proven. In addition, in vivo testing has not yet been 
done. Although ObLiGaRe results in precise gene editing, there will be an addition of 
half a ZFN target site in the genome, precluding fully precise gene repair. 
Homology-independent targeted integration (HITI), devised by Suzuki and colleagues 
[12] and broadly tested in vitro and in vivo, is another knock in NHEJ-based strategy very 
similar to the ObLiGaRe-based method. The difference between the two methods is the 
type of nuclease used: while HITI uses the CRISPR system, ObLiGaRe is based on obligate 
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heterodimeric ZFNs or TALENs. For HITI, the donor sequence is flanked by one or two 
(for the circular or linear donors respectively) sgRNA target sites (Figure 2a and 2c). 
There is a third identical sequence, but in the reverse orientation, in the target locus 
wherein the donor DNA is pasted. This approach supports knock-in of a sequence, 
mostly in the correct orientation, as an intact sgRNA target sequence persists when 
recombination occurs in the reverse orientation. HITI permits knock-in in both dividing 
and non-dividing cells. Using the HITI strategy in primary neurons, ±90% of the targeted 
cells showed precise insertion of the HITI donor. HITI was also tested to knock-in an 
entire exon in the Royal College of Surgeons rats, a well-established model for retinitis 
pigmentosa. Analysis of the DNA sequence from the targeted eyes showed precise 
integration of the HITI donor with a frequency of ±30% at 3’ junctions and 95% at 5’ 
junctions. Different frequencies of indels were also observed following HITI-based gene 
editing in other organs, including brain, liver, heart and muscle. Thus, HITI can result in 
NHEJ-based precise gene editing, but does not exclude non-precise editing outcomes. 
Cas12a (former Cpf1) is a class II type V endonuclease causing staggered cuts, creating a 
5 bp long 5’ overhangs [16, 26]. The produced sticky ends created by Cas12a/Cpf1 are 
particularly advantageous for NHEJ based gene editing, allowing insertion of a donor in 
the correct orientation in dividing and non-dividing cells. Aside from making sticky ends, 
there are other features of Cas12a/Cpf1 that make this enzyme an interesting choice, 
especially for in vivo applications. These include (i) pre-crRNA self-processing 
(simplifying multiplex genome editing); (ii) no need for a tracRNA by which Cas12a/Cpf1 
is 140 amino acids smaller than Cas9; (iii) a T rich PAM recognition site allowing 
application in AT rich sequences; (iv) and having little to no off-target effects in human 
cells  [16, 27, 28]. Although it is theoretically possible to deploy the staggered ends 
made by Cpf1 for NHEJ-mediated precise gene repair in non-dividing cells, this has not 
yet been experimentally demonstrated. The Cas12b (former C2c1) is another type V 
system making staggered cut sites, resulting in a 7 base-pair overhang, that could be 
used for sticky end NHEJ-mediated gene editing [26, 29].  
Microhomology-mediated end-joining (MMEJ)- based strategy 
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MMEJ is an alternative NHEJ repair pathway independent of Ku, that uses 
microhomologous sequences of 5-25 nucleotides, flanking the DSB, to join the broken 
ends [30]. While NHEJ preferentially operates in G1, MMEJ occurs predominantly in the 
G2 and S phases. Although limited end resection with slower kinetics is possible in G1 
cells, this might be sufficient is for most MMEJ processes. Therefore, this pathway could 
potentially be harnessed to perform gene editing in non-dividing cells. The precise 
integration into target chromosome (PITCH) strategy, described by Nakade and 
colleagues, is based on the MMEJ pathway [31]. PITCH employs either TALENs or 
CRISPRs. CRISPR-mediated PITCH (CRIS-PITCH) is based on the incorporation of two 
different sgRNA target sites flanking the sequence to be knocked-in (Figure 2d and 2e), 
and a third sgRNA site in the target locus. The three different sgRNA are designed such 
that they will produce micro-homologous regions following DSB. This micro-homology 
determines the correct orientation of ligation. Using the PITCH approach, a targeted 
knock-in was performed in silk worm and frog embryos, as well as primary neurons. 
Although precise knock-in was shown in targeted cells, unwanted non-precise outcomes 
bearing insertions and deletions were also observed [12, 31].  
Homology-mediated end joining (HMEJ)-based strategy   
HMEJ uses a donor construct with ±800 bp homology arms flanked by sgRNA sites. To 
create a knock-in, the donor construct will be cut out from the backbone inside the cell 
by co-delivered sgRNAs . HMJE allowed precise in vivo targeted knock-in in adult mouse 
brain and liver with efficiencies greater than either MMEJ, NHEJ or HDR. It was shown 
that the repair pathway involved in HMEJ-based editing of non-dividing cells, although 
homology dependent, is different from HDR [13]. However, further investigations will be 
needed to elucidate the molecular mechanism involved in HMEJ-based DNA repair. 
RecCas9-based strategy 
RecCas9 was generated by Chaikind and colleagues, by fusing dead Cas9 (dCas9) to a 
serine recombinase catalytic domain [17]. The RecCas9 fused protein could be used as a 
donor-dependent strategy to create insertions, or as a donor-independent method to 
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cause deletions, inversions or chromosomal translocations, based on the substrate 
orientation (Box 3). Using RecCas9, Chaikand and colleagues demonstrated that a 
seamless deletion of 14kb size could be created in a genomic sequence of human cells. 
However, an attempt to create an insertion failed, and whether or not RecCas9 can 
catalyse insertions is still to be determined. RecCas9 recognizes endogenous target sites 
in the genome. However, there are only 450 target sites for RecCas9 in the genome. 
Replacing Gin recombinase with other recombinases and/or using other types of CRISPR 
systems with different PAM sequences, might expand the target sites, and overcome 
this limitation. Because RecCas9 mediates recombination-independent DNA repair, it 
might be more efficient than all other programmable nucleases in non-dividing cells. 
Transcription coupled (TC) DSB repair (TC-DSB)-based strategy  
Even if non-dividing cells do not transfer genetic information to other progenies, their 
long-term genome stability is crucial. Therefore, DSBs in actively transcribed genes need 
to be repaired with sufficient accuracy [32] . One such mechanism might be DNA repair 
coupled with transcription termed transcription coupled NER (TC-NER), which has been 
suggested long ago [32-35]. It has also been reported that RNA, rather than DNA, can be 
used as a template for DNA repair at transcriptionally active sites in both yeast and 
human cells [33, 34, 36-41]. Moreover, there is evidence that the HDR pathway can use 
an RNA transcript-template to edit DNA in active transcriptional sites damaged by DSB 
of human cells in the G0/G1 phase. These studies challenge the view that HDR occurs 
only in the G2 or S phase and the traditional view that HDR requires DNA as a template 
[11, 39]. Concordantly a recent study demonstrated that HDR in non-dividing 
cardiomyocytes does not depend on S-phase entry [42]. Using adeno-associated virus 
(AAV) to carry the HDR donor, efficient precise correction was achieved in 
cardiomyocytes in vivo in mice. Another study suggested that NHEJ but not HDR was 
involved in error-free repair of DSBs in active genes of human cells, using the nascent 
RNA as a template [40]. A strong association between NHEJ factors and transcription 
was observed, with increased levels of NHEJ when transcription was induced [40]. 
Another report demonstrated that homologous chromosomes in human cells in in 
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G0/G1 initiate contact at DSB sites in transcribed regions [43], while yet another study, 
using genome wide profiling, described accumulation of HDR proteins at active 
transcription sites [36]. Thus, even if mechanisms underlying RNA templated DNA repair 
in non-dividing cells needs further elucidation, this concept has a direct application with 
regard to precise gene repair in non-dividing cells. 
Donor-dependent strategies: possible approaches and pitfalls 
ObLiGaRe, HITI, PITCH and HMEJ can be used to reverse deletion mutations resulting in 
exon skipping, or whole exon deletions, by inserting a complete exon (insertion 
approach). These strategies can also be used to correct mutations by knocking in the 
cDNA of a full gene or part of a gene (downstream of the mutation), maintaining RNA 
transcription under the control of the native promoter (Figure 1). In addition, ObLiGaRe, 
HITI, PITCH and HMEJ can also be used to replace a mutant by a wild-type sequence 
(replacement approach) (Box 3). RecCas9 could theoretically also be applied to reverse 
such mutations by inserting new sequences, although RecCas9 mediated deletion is 
much more efficient than insertion. Cas12a, on the other hand, may not be suitable for 
correction of a deletion, as reconstruction of the cut-site following donor integration 
cannot be excluded (Box 3). 
Donor-dependent strategies are different (i) in the precision of the design and the 
possibility of predicted unwanted outcomes, (ii) the efficiency of the strategy in non-
dividing cells, (iii) and the frequency of additional mutations.  
(i) While HITI and ObLiGaRe result in the addition of half a ZFN/sgRNA target site in the 
genome, HMEJ, PITCH and RecCas9 do not pose this design limitation. However, 
although PITCH and HMEJ strategies use microhomologous and homologous sequences 
to enable the correct direction of the insert integration, they do not preclude unwanted 
editing outcomes such as NHEJ mediated ligation of the insert in both correct and 
reverse orientations, irrespective of homologies [12]. This unwanted outcome is more 
likely for the PITCH than the HMEJ approach. The disadvantage of the HITI and 
ObLiGaRe strategies, namely the incorporation of half a ZFN/sgRNA target site in the 
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genome, has, however, the benefit that insertion in the reverse orientation is 
disfavoured.  
(ii) The efficiency of different methods has only been compared in a few studies. Suzuki 
and colleagues demonstrated that the knock-in efficiency by the HITI-approach is higher 
compared to PITCH and HDR in both dividing and non-dividing cells in vitro, and more 
efficient than HDR in non-dividing cells in vivo [12]. Yao and colleagues found that the 
efficiency of HMEJ was higher than NHEJ, PITCH and HDR, as they demonstrated that 
HMEJ much more efficiently corrected mutated genes in adult brain and liver than 
either MMEJ, NHEJ (simple NHEJ not by HITI), or HDR in liver [13]. Comparisons between 
RecCas9 or ObLiGaRe approaches and other approaches have not yet been published. In 
any case, more studies are needed to further define the efficiency of performing all 
donor-dependent strategies. 
(iii) The occurrence of indels has been observed in all NEHJ/MMEJ/HMEJ approaches, 
with variable frequencies between different strategies and different tissues [12, 13]. 
Therefore, designing the ZFN/sgRNA target sequences in less sensitive intronic regions 
might prevent undesired consequences. Indels did not occur using RecCas9 for deletion 
[17].  
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Donor independent strategies for in vivo genome editing in non-dividing cells 
Donor independent strategies do not require HDR, therefore they should be possible in 
non-dividing cells. Any type of programmable nuclease can potentially be used 
independent of a donor to perform NHEJ based gene editing. Donor independent 
strategies include Base-editing- or RecCas9-mediated gene editing.  
Base editing strategy 
Base editing was originally described by Komor and colleagues, by engineering the base 
editor (BE) (for a review on base editing systems see [44]). BE is an engineered Cas9 
cytidine deaminase fusion enzyme that creates a C to T (or G to A) conversion within 
positions -16 to -12 from the PAM sequence [15]. Since the initial description, BE has 
been extensively improved and expanded. The initial BE (BE1) fused a dCas9 to Cytidine 
deaminase from rat (rAPOBEC1). Although BE1 showed efficient conversion of C to T in 
cell-free experiments, a much lower efficiency was observed in cells, because cells repair 
U:G mismatches causing U excision by uracil DNA glycosylase (UDG) as a part of the base 
Excision Repair (BER) pathway, and reversion of the U->G to C->G. To overcome this 
problem a second BE (BE2) was generated wherein an UDG inhibitor (UGI) was added to 
BE1, increasing the efficiency by three-fold.In the third iteration (BE3), dCas9 was 
replaced by a Cas9-nickase-D10A which nicks the non-edited strand (G), as the 
mismatch repair (MMR) pathway prefers to correct the base on the nicked strand. 
Therefore, the mismatched U-G is replaced by U-A and the desired T-A is formed upon 
DNA repair or replication. BE3 was 6-fold more efficient than BE2. BE3 was further 
upgraded to BE4, by adding two copies of UGI, optimizing the linker, and adding a GAM 
protein [45]. GAM proteins (from Mu bacteriophage) bind and protect DSBs that can 
occur because of two nicks, which in the BE4 strategy can be caused by BER combined 
with the nick caused by Cas9-nickase-D10A on the opposite strand. YEE-BE3 is another 
iteration of BE3 which has an activity window of 1-2 bases precluding the unwanted C to 
T conversion, although this conversion always results in silent mutations if this occurs in 
the third position of a codon [46]. BEs have been delivered in vivo to the murine inner 
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ear (by lipid nanoparticle) and liver (adenoviral vector), yielding gene editing efficiencies 
of 34% and 1.5%, respectively [15, 47, 48]. Target-AID is another base editing system 
which uses a D10A Cas9 nickase and UGI, similar to BE3. This system uses a different 
cytidine deaminases and protein fusion sequence [49]. 
RecCas9 strategy 
RecCas9, also described above for donor-dependent approaches, can successfully be 
used to create a deletion in a donor-independent strategy, to reverse translocation 
mutations provided that the recombinase recognition sites are present flanking the 
translocated sequences. Another mutation that might be reversed by RecCas9 is an 
inversion, provided that suitable substrate does exist flanking the inverted region. 
Further investigation of additional RecCas9 recognition sites might make these 
applications possible (Box 3). 
Donor-independent strategies: possible approaches and pitfalls 
Some types of mutations that can be corrected by donor independent strategies include 
among others, gain of function (GOF) mutations, inversions, translocations, 
substitutions, insertions, duplications or mutations that can be reversed by indels, as 
long as loss of one intact copy of the gene does not cause disease.  
Deletions can be created by using a pair of sgRNAs together with Cas9 or other CRISPR 
systems, two pairs of ZFN or TALEN, leading to repair by NHEJ. One needs to, however, 
be cognizant that creation of indels, which might consist of multiple bp, could 
unexpectedly disrupt non-coding RNAs [50-53]. Alternatively, recCas9 could also be used 
to perform deletions, provided that recognition sequences are present flanking the 
target site.  
One problem with removal of insertions and duplications, is that when two sgRNA and 
Cas9 are used, it is possible that the sequence between the two sgRNAs can re-integrate 
in a reverse orientation, which will block the sgRNA recognition sites and lock the insert 
inside the target site, however we provide suggestions to circumvent this problem (Box 
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3). Deletion approaches can target GOF mutations, mutations reversible by exon 
skipping and intronic cryptic splicing site mutations  
Generally, for GOF mutations knocking out the gene is enough to reverse the phenotype 
as long as hemizigousity does not create a LOF phenotype. The main problem for 
genome editing of GOF mutations, regardless of the cell type, is that discriminating 
between the mutant and wild type allele using programmable nucleases especially 
CRISPR-Cas9 when the mutation is a single base substitution or loss of one or a few bps.  
However, mismatch at even one (or a few) bp is not tolerated when these are located in 
the ‘sensitive core’ (-16 to -13 of the PAM sequence of SpCas9; or between 1 and 18, 
except 8 and 9 distal to the PAM protospacer positions for Cas12a) [54, 55]. Therefore, 
allele specific knock out of GOF mutations could be possible if for example sgRNAs are 
chosen such that the mutation or a polymorphism in the diseased allele falls within this 
sensitive core. Alternatively, one could exploit the possibility that the mutant allele 
differs from the wild type in a PAM disturbing nucleotide, either due to the mutation 
itself or a polymorphism in the gene sequence [56] .  
NHEJ induced indels can also be used to reframe a frameshift LOF mutation or to disrupt 
a frame in GOF mutations. Although the result of reframing will likely not be precise, as 
a few bases may be deleted, this might be tolerated in some genes  [57].  
Base editing approaches can be used to target T>C substitution mutations in non-
dividing cells [15]. Other substitutions could be correctable by using different types of 
deaminases and expanding the substrate of BEs in the future. Base editing approaches 
could also be used to knock-out GOF mutations by creating a stop codon via substitution 
of C by T or G by A in glutamine, arginine or tryptophan codons [47, 58]. 
RecCas9 has been used to create deletions, although adaptations will be needed to 
expand the substrate sequences.  
Other donor independent approaches are inversion and translocations. However, the 
efficiency of such approaches for in vivo gene therapy in non-dividing cells is not clear 
yet (Box 3).  
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Box 3. Further evaluation and / or adaptations required to current methods of genome editing in non-
dividing cells: 
A number of the candidate donor-dependent and -independent gene editing approaches described, lack 
experimental proof of concept, and / or require further optimisation.  
Donor dependent replacement approach  
These are methods to replace a mutant sequence in the target locus with a donor template. RecCas9 
could be used to replace any mutation by catalysing cleavage, strand-exchange and re-ligation of the 
donor DNA [17]. Cas12a/Cpf1-based NEHJ could in principle be used in a replacement approach, by 
combining four different sgRNAs. The sgRNAs should then be designed such that compatible sticky ends 
are created between the insert and the target locus. To lock the insert and prevent subsequent removal 
of the integrated insert, a synonymous mutation that disrupts the PAM sequence in the insert should 
be included. Theoretically, this approach would be able to correct any type of mutation. 
Extrapolating the CRISPR-mediated precise integration into target chromosome (CRIS-PITCh), 
homologous-mediated end joining (HMEJ), homology-independent targeted integration (HITI) and 
Obligate Ligation-Gated Recombination (ObLiGaRe) to a donor-dependent replacement approach, is in 
principle possible. However, the predicted unwanted outcomes such as, inversions and deletions of 
mutant sequence in all of these methods, and unwanted NHEJ mediated ligation of the insert, when 
using PITCh and HMEJ, make these designs not suitable for in vivo applications. 
Donor independent inversion vs. deletion approach 
Simple cutting of any sequence using a pair of sgRNA and a SpCas9 might result in either deletion or 
inversion of the excised sequence. However, it is possible to disfavour one of these events by using 
obligate heterodimeric ZFN and TALEN, or Cas9-FokI (figure I). Alternatively, RecCas9 can mediate 
inversions if a substrate sequence is present. Removal of an inverted sequence with a pair of sgRNA has 
been performed by RecCas9, to reverse a haemophilia mutation in vitro or cancer modelling in vivo, but 
exploration to an in vivo therapeutic application in preclinical models is still needed [59, 60]. 
Donor independent translocation approach 
Translocation mutations can be categorized based on the number of DSBs involved into four classes: 
simple (one), reciprocal (two), transposition (three) and complex (more than three DSBs) 
translocations.  In vivo and in vitro models of reciprocal translocations have been created using 
recombinases and the CRISPR system [61, 62]. The possibility to use such an approach to reverse 
translocation mutations for therapeutic purposes will however, require further work. 
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Box 4.  Additional applications of gene editing strategies in non-dividing cells:  
Targeting other cell types 
Strategies suitable for gene editing in non-dividing cells could be used to target stem cells that are 
known to be quiescent (G0) in the diseased organ, and thus create a reserve of edited stem cells for 
tissue regeneration. This is especially important in high turnover tissues such as epidermis, where 
editing the rapidly dividing transient amplifying pool will only temporarily correct mature skin cells, 
while correcting stem cells would lead to long-term therapeutic effects [63].  
As non-HDR methods are also more efficient than HDR, even in dividing cells [12, 15], strategies 
described for non-HDR mediated gene editing could also be used in dividing cells for both in vivo and ex 
vivo gene editing.  
More than correcting a gene 
In addition to correcting a mutation, in vivo gene editing strategies for non-dividing cells would also 
allow insertion of a therapeutic gene in a ‘safe harbor’. For instance, precise HDR mediated knock in of 
proteins in hepatocytes downstream of the albumin promoter, may represent a universal platform for 
the production of secreted proteins (e.g. human factors VIII and IX for hemophilia A and B) or proteins 
that can be taken up by diseased cells (e.g. lysosomal enzymes for mucopolysaccharidosis) [64, 65]. This 
platform is especially important because it provides a permanent therapy for a diverse range of genetic 
and non-genetic disorders. Similarly, non-HDR strategies such as homology-independent targeted 
integration (HITI), obligate ligation-gated recombination (ObliGaRe), precise integration into target 
chromosome (PITCh) or homology-mediated end-joining (HMEJ) could be used to insert any sequence 
of interest in a desired locus in non-dividing cells via an insertion approach (figure).  
Gene editing in organ cultures 
Methods for in vivo gene editing in non-dividing cells could also be used to ex vivo gene edit donor 
explants or organ cultures. Donor explants, that can be maintained in culture, such as cornea, would be 
a candidate for such manipulations. Alternatively, genome manipulation of non-dividing cells in human 
brain slice for instance for applying optogenetic tool, could also be achieved by for instance HITI, which 
is highly efficient in primary neurons [12, 66, 67].  
Modeling disorders based on somatic mutations 
In vivo manipulation of non-dividing cells could be used to model disorders based on somatic mutations 
in mature non-dividing cells, such as cancer and neurological disorders [68]. Base editor (BE), in 
particular,  could be used to model cancer, as more than 50% of nonsense mutations across all cancers 
result in a stop codon,  and >50% of such stop codons could be created by BE [58].  
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Conclusion and future perspectives 
In vivo gene editing using programmable nucleases including the CRISPR system, 
constitutes the only approach for curing many genetic disorders. Low efficiency of the 
HDR repair pathway in non-dividing cells, which is the status of differentiated cells in 
almost all organs, does, however, limit the use of this technology to only a few 
conditions. Nevertheless, alternative repair pathways or strategies discussed in this 
review are being developed to overcome this hurdle, even if some of these strategies 
have not been fully tested in vivo and in non-dividing cells. Additionally, transcription-
coupled DSB repair (TC-DSB) repair in non-dividing cells, if proven to be efficient, could 
be co-opted to artificially enable gene editing in non-dividing cells. We also discuss that 
type of mutation dictates which editing approach will be more suitable. Finally, we 
discuss that problems with editing efficiency frequency, and the possibility of unwanted 
outcomes exist with different of these approaches, and are important factors that 
should be taken into account when choosing a specific method. There are still more 
questions and uncertainties which have to be addressed before proceeding to clinic, 
that have been summarised in ‘Outstanding Questions'. 
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Legends: 
Figure 1. Candidate gene editing approaches for non-dividing cells in vivo.  
(a and b) Donor-independent approaches, (c and d) donor-dependent approaches. 
Boxes with dash outlines are potential approaches which insufficient experimental proof 
that they can edit genes in vivo in non-dividing cells exists (b and d).  In each box 
approaches (in bold letters) and strategies are listed in the left column, targetable 
mutations for each approach are listed in the middle column, and schematic 
representation of each approach is shown in the right column.  
(right column): an exon in pink color, and a red star indicate the mutated exon; dashed 
lines show splicing pattern; green triangles represent the manipulation site; Stop: stop 
codon; PA: poly A sequence.  
(box ‘a’): the cryptic exon (crypt ex) is shown as an example.  
(box ‘c’):  pink exon2 with a jagged side represent a deletion. 
(abbreviations used) BE: base editor, BE 3, BE4 and YEE BE3 are other BE developed 
from BE3, HITI: Homology-independent targeted Integration, HMEJ: Homology-
mediated end Joining, ObLiGaRe: Obligate Ligation-Gated Recombination, PITCH: Precise 
integration into target Chromosome, recCas9: recombinase Cas9, Target-AID: a base 
editing system very similar to BE3 using a different cytidine deaminase. 
 
 Figure 2. The principal of ObLiGaRe, HITI and CRIS-PITCH gene editing strategies  
(a) Homology-independent targeted Integration (HITI)/ Obligate Ligation-Gated 
Recombination (ObLiGaRe) strategies for targeted knock in (insertion approach) (d) 
CRIS-PITCH. As an example of a target mutation, exon 2 deletion is shown as a pink exon 
with a jagged side. A pair of pentagons represent a arget site for sgRNA/ZFN/TALEN. A 
black scissor indicates cleavage and a grey scissor with a red cross indicate that no 
cleavage occurs and the insert is locked.  
(b) Mechanism of ObLiGaRe strategy, wherein Heterodimeric obligated ZFN are used to 
ensure the correct orientation of inset ligation. The ZFNs/TALENs make a DSB cut only if 
two arms on the opposite strands make heterodimers, which is the case for the target 
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locus but not homodimers (targeted locus) through a modified FokI nuclease domain 
preventing cleavage of the targeted locus.  
(c) Mechanism of HITI strategy, wherein the insert is locked in the correct orientation 
using CRISPR/Cas9. Integration of the insert with correct orientation creates 
palindromes of a part of sgRNA site (two blue/two pink pentagons) that prevent 
recleavage of the insert   
(e) Mechanism of the CRIS-PITCH strategy demonstrating how microhomologous 
sequences on the donor and target sequence are formed by CRISPR-Cas9. The sgRNAs 
target sites are not resent in the targeted locus preventing Cas9 recleavage. 
(abbreviations used) 
 
Box 1 Figure I. CRISPR/Cas9 system. Cas9 and sgRNA targeting a sequence protospacer, 
provided that a 3’ PAM sequence is present (NGG). The cutting site is shown with black 
scissor and located 3 bases upstream from the PAM sequence. 
 
Box 3 Figure I. Potential strategies to favour deletion or inversion of a target sequence. 
The strategies are based on obligated heterodimeric ZFN pairs that can be replaced by 
TALEN or Cas9-FokI. Pentagon pairs are ZFN target site. The variant FokI cleavage 
domain is depicted in a drop or three-quarter circle.   
(a) When there are identical variant FokI cleavage domains fuse to the ZFN on the 
sequence that has to be excised from target locus (pink and green ZFNs), deletion is the 
stable outcome. This is because the inverted sequence reconstructs the ZFN 
heterodimers (green-blue & pink-yellow pairs).  
(b) When the variant FokI cleavage domain on the sequence that has to be excised from 
target locus are different, inversion is the desired outcome. This is because the deletion 
outcome results in reconstruction of the ZFN heterodimer (Blue-yellow pair).  
(abbreviations used) 
 
Outstanding Questions Box 
1. Is the risk inherent to strategies that are mainly based on DSB repair pathways (except from 
recCas9 and base editor) for translocations, and hence tumorigenesis? 
2. What are the differences in DNA repair pathways used between quiescent, e.g. stem cells that 
are quiescent but can undergo replication, and terminally differentiated post-mitotic cells such 
as neurons (but e.g. not hepatocytes), that in theory cannot re-enter cell cycle? Or even 
between different single cells of a given tissue? How does this affect the efficiency of gene 
editing? 
3. Is RNA-templated DNA repair an alternative for what is considered faithful DNA repair, namely 
HDR, in non- dividing cells? Is it possible to co-opt this approach to perform precise gene editing 
in these cells? 
4. Does the variability in inserts and deletions (INDEL) frequencies in different organs seen with the 
Homology-Independent Targeted Integration (HITI) approach also occur when other approaches 
are used; and what lays at the basis of this? 
5. Is it possible to exploit Cas12a as an approach to target a wide range of mutations? Do the 
complementary sticky ends created by Cas12a allow accurate NHEJ-based gene repair? 
6. Is it possible to in vivo correct inversions or translocations with therapeutically acceptable 
efficiencies? 
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